-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Ocular Therapeutix, Maintains $18 Price Target

Benzinga·09/29/2026 09:46:18
Listen to the news
Needham analyst Serge Belanger reiterates Ocular Therapeutix (NASDAQ:OCUL) with a Buy and maintains $18 price target.